An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Study summary

The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986205 and Nivolumab

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 28, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?47 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Bristol-Myers Squibb
Interventions being studied: Drug: BMS-986205; Drug: Nivolumab; Drug: Ipilimumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com
During dose escalation, subjects with advanced solid tumors that have progressed following at least one standard regimen
During cohort expansion, subjects with advanced cancer that either have received at least one prior therapy or are treatment naive, depending on the specified tumor type
Subjects must have measurable disease
Subject must consent to provide previously collected tumor tissue and a tumor biopsy during screening.
At least 4 weeks since any previous treatment for cancer
Must be able to swallow pills or capsules
Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1

Reasons someone may not be able to joinExclusion criteria

Active or chronic autoimmune diseases
Uncontrolled or significant cardiovascular disease
History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)
Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma)
Active central nervous system (CNS) metastases and CNS metastases as the only sites of disease
Active infection Other protocol defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Local Institution - 0028Tucson, Arizona
Local Institution - 0026La Jolla, California
Local Institution - 0035Tampa, Florida
Local Institution - 0005Atlanta, Georgia
Local Institution - 0048Atlanta, Georgia
Local Institution - 0027Chicago, Illinois
Local Institution - 0051Lutherville, Maryland
Local Institution - 0049Detroit, Michigan
Local Institution - 0006St Louis, Missouri
Local Institution - 0033Hackensack, New Jersey
Local Institution - 0041New York, New York
Local Institution - 0030Cleveland, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 28, 2023. Always confirm current availability with the study team.

View original record ↗